Ouro Medicines

Biotech & Life Sciences · South San Francisco, United States · Founded 2024

Ouro Medicines is a biotechnology company focused on developing immune reset therapeutics aimed at treating chronic immune-mediated diseases. The company operates in the biopharmaceutical sector, targeting patients who suffer from conditions that involve the immune system. Ouro Medicines leverages its scientific expertise and a strong track record in advancing cell-depleting therapies through clinical stages. The business model revolves around research and development, with a significant portion of its funding directed towards creating novel T cell engagers that have the potential to reset the immune system. Ouro Medicines generates revenue through partnerships and collaborations, as well as through the development and commercialization of its therapeutic assets. The company was founded by Monograph Capital in collaboration with GSK and has secured substantial funding from investors such as TPG, NEA, and Norwest. With a promising clinical stage asset and a robust discovery pipeline, Ouro Medicines is positioned to redefine treatment paradigms for immune-mediated diseases. Keywords: biotechnology, immune reset, therapeutics, chronic diseases, T cell engagers, clinical pipeline, biopharmaceutical, research, development, partnerships

Valuation $1–2.5B

Headcount <100

Total funding $100–500M

Unlock exact values

Investors

8 investors on Ouro Medicines's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 8 investors entered at this stage

TPG

NEA

Norwest Venture Partners

UPMC Enterprises

GSK

Zoo Capital

Monograph Capital

LongRiver Investments

Global footprint

Where Ouro Medicines has talent and traffic

Workforce by country

2 countries with
team presence

🇺🇸 United States90.5%

🇬🇧 United Kingdom9.5%

2 countries shown

Talent graph

The shape of Ouro Medicines's talent

Dealroom maps Ouro Medicines's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

5 team members profilednamed & role-tagged by Dealroom

25 employeestotal headcount

2 executives & foundersidentified by name

DimensionScore

AI Talent

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Ouro Medicines's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about Ouro Medicines

An AI-synthesized read of the highest-engagement posts about Ouro Medicines on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ouro Medicines on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles